Myriad Genetics, Inc. (NASDAQ:MYGN) Holdings Raised by XTX Topco Ltd

XTX Topco Ltd raised its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 474.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 64,080 shares of the company's stock after acquiring an additional 52,923 shares during the period. XTX Topco Ltd owned 0.07% of Myriad Genetics worth $879,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in MYGN. Sterling Capital Management LLC boosted its stake in Myriad Genetics by 829.9% in the 4th quarter. Sterling Capital Management LLC now owns 2,864 shares of the company's stock worth $39,000 after buying an additional 2,556 shares during the last quarter. KBC Group NV boosted its position in shares of Myriad Genetics by 132.8% in the fourth quarter. KBC Group NV now owns 5,845 shares of the company's stock worth $80,000 after acquiring an additional 3,334 shares during the last quarter. Inspire Advisors LLC increased its position in Myriad Genetics by 48.1% during the fourth quarter. Inspire Advisors LLC now owns 11,226 shares of the company's stock worth $154,000 after purchasing an additional 3,644 shares during the last quarter. E Fund Management Co. Ltd. acquired a new position in Myriad Genetics during the fourth quarter worth approximately $161,000. Finally, Entropy Technologies LP acquired a new position in shares of Myriad Genetics in the 4th quarter valued at $178,000. Hedge funds and other institutional investors own 99.02% of the company's stock.

Myriad Genetics Stock Down 3.4 %

MYGN stock traded down $0.27 during midday trading on Friday, hitting $7.64. 1,606,449 shares of the company's stock were exchanged, compared to its average volume of 910,692. The stock has a market capitalization of $704.19 million, a price-to-earnings ratio of -5.88 and a beta of 1.87. Myriad Genetics, Inc. has a 12-month low of $7.35 and a 12-month high of $29.30. The firm has a 50 day moving average price of $10.24 and a 200-day moving average price of $14.33. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). The company had revenue of $210.60 million during the quarter, compared to the consensus estimate of $210.35 million. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. During the same period last year, the business posted ($0.12) EPS. On average, analysts anticipate that Myriad Genetics, Inc. will post -0.3 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on MYGN shares. Raymond James reaffirmed an "outperform" rating and issued a $19.00 target price (down from $27.00) on shares of Myriad Genetics in a research report on Tuesday, February 25th. Guggenheim cut Myriad Genetics from a "buy" rating to a "neutral" rating in a report on Wednesday, April 9th. Piper Sandler upgraded shares of Myriad Genetics from a "neutral" rating to an "overweight" rating and raised their price target for the company from $11.50 to $12.50 in a report on Wednesday, March 12th. The Goldman Sachs Group decreased their price objective on shares of Myriad Genetics from $18.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday. Finally, UBS Group cut their target price on shares of Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 25th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $20.61.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.